Please login to the form below

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Alderley Park, UK, January 2020

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis.

The IND is a crucial milestone in the continued development of BB2603, a nanoformulated, topical form of terbinafine for the treatment of onychomycosis (fungal toenail). With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.

The primary outcome of this study is to look at the efficacy BB2603 in onychomycosis, with a secondary dose finding outcome also being investigated.

John Ridden, CEO said: “Having received clearance from the FDA we are looking forward to the opportunity to work with over 20 international sites on the Phase IIb trial of BB2603 with the first patient expected to be recruited in March 2020.This is a key milestone in our path to commercialisation of our nanotechnology product portfolio.”

With BB2603, Blueberry Therapeutics aim to maintain the efficacy of the oral gold standard treatment, but at a lower dose. Delivering the active pharmaceutical ingredient using nanotechnology ensures it penetrates across the nail plate and reaches the target site of action in a controlled manner, meaning lower doses can be used and systemic side effects are minimised.

ENDS

Blueberry Therapeutics Limited Media Contact

Elle Bell – Onyx Health

ebell@onyxhealth.com

Tel: +44 (0) 191 640 3638

Notes to Editors

About Blueberry Therapeutics Limited

Blueberry Therapeutics Ltd., incorporated in November 2011, is a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections.  The company is using its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.

Blueberry Therapeutics combines expert in-house resources with selected outsource partners and collaborators to take projects through from preclinical research onto de-risked human clinical proof of concept and then on to the market. For more information, please visit http://www.blueberrytherapeutics.com

3rd February 2020

Share

Tags

Company Details

ahair@onyxhealth.com

Website

Address:
Generator Studios, Trafalgar Street
Walker Road
Newcastle Upon Tyne
England
NE1 2LA
United Kingdom

Latest content on this profile

Onyx Health Joins Forces with Rare Disease Specialists Actigen
Onyx Health will be working with Actigen to raise awareness of their innovative clinical trial work in rare diseases and the need to develop new treatment solutions.
ahair@onyxhealth.com
Onyx Health Announces a "Double Hatrick" of New Appointments
Onyx Health continues to expand with six new appointments to its creative and communication teams, due to increased growth in its international client portfolio work.
ahair@onyxhealth.com
Onyx Health Tackles Type 2 Diabetes with Diabetes Lifestyle Doctors
Onyx Health has teamed up with Diabetes Lifestyle Doctors to tackle the diabetes care gap in the NHS and help patients suffering from type 2 diabetes across the UK. (Pictured Louise Flintoft, Associate Director at Onyx Health)
ahair@onyxhealth.com
Onyx Health Announces Two Top Appointments
Onyx health have made two senior appointments to their communications team
ahair@onyxhealth.com
Onyx Health Marks Record Growth with Six New Appointments
Onyx Health has expanded its communications team with six new appointments, after more than doubling its fee incomes and expanding its international client portfolio over the past year
ahair@onyxhealth.com
Onyx Health Launch Creative Studio After Record Year
Healthcare marketing communications specialists Onyx Health have set up a new creative studio following a year of record income growth and international client expansion.
ahair@onyxhealth.com